Pursuant to SEBI Circular CIR/CFD/CMD1/162/2019 dated 24th December, 2019 (as amended) and Regulation 32(1) of SEBI (LODR) Regulations, 2015, Shukra Medtech Limited has submitted a compliance disclosure confirming no deviation or variation in the utilization of proceeds from its preferential issue.

Key Quantitative Figures

  • Number of Warrants Issued: 46,43,000 (Forty Six Lakhs Forty Three Thousand) convertible warrants
  • Issue Price: ₹1 per warrant (including both Warrant Subscription Price and Warrant Exercise Price)
  • Amount Raised: ₹10,46,33,630 (Rupees Ten Crores and Forty-Six Lakhs Thirty-Three Thousand Six Hundred Thirty Only)
  • Percentage Received: 75% of consideration amount received from allottees as required under SEBI ICDR Regulations

Fund Utilization Details

Funds were utilized exactly as per the original objects approved in the EGM:

| Purpose | Amount Allocated (₹ lakhs) | Amount Utilized (₹ lakhs) | Deviation |

| Working Capital requirement and Bank Guarantee margin | 575.57 | 575.57 | Nil |

| Capital expenditure in Subsidiary Companies | 422.77 | 422.77 | Nil |

| General Corporate Purposes | 45.00 | 45.00 | Nil |

Review and Approval

  • The statement of deviation was duly reviewed by the Audit Committee
  • Audit Committee comments: "No Comments"
  • Auditor comments: "No Comments"
  • No monitoring agency was appointed for this fund raise

Financial Impact

No financial impact from deviation as there has been no deviation in fund utilization. The company has utilized the entire ₹10.46 crore exactly as per the original objects disclosed to shareholders.

Capital Structure Impact

The preferential issue involved issuance of 46,43,000 convertible warrants at ₹1 per warrant, representing potential future equity dilution upon conversion.